Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A. Turner N, et al. Among authors: natrajan r. Cancer Res. 2010 Mar 1;70(5):2085-94. doi: 10.1158/0008-5472.CAN-09-3746. Epub 2010 Feb 23. Cancer Res. 2010. PMID: 20179196 Free PMC article.
Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.
Naidoo K, Wai PT, Maguire SL, Daley F, Haider S, Kriplani D, Campbell J, Mirza H, Grigoriadis A, Tutt A, Moseley PM, Abdel-Fatah TMA, Chan SYT, Madhusudan S, Rhaka EA, Ellis IO, Lord CJ, Yuan Y, Green AR, Natrajan R. Naidoo K, et al. Among authors: natrajan r. Mol Cancer Ther. 2018 Jan;17(1):306-315. doi: 10.1158/1535-7163.MCT-17-0760. Epub 2017 Nov 13. Mol Cancer Ther. 2018. PMID: 29133620 Free PMC article.
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.
Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, Song F, Rafiq R, Konde A, Krastev DB, Menon M, Campbell J, Gulati A, Kumar R, Pettitt SJ, Gurden MD, Cardenosa ML, Chong I, Gazinska P, Wallberg F, Sawyer EJ, Martin LA, Dowsett M, Linardopoulos S, Natrajan R, Ryan CJ, Derksen PWB, Jonkers J, Tutt ANJ, Ashworth A, Lord CJ. Bajrami I, et al. Among authors: natrajan r. Cancer Discov. 2018 Apr;8(4):498-515. doi: 10.1158/2159-8290.CD-17-0603. Cancer Discov. 2018. PMID: 29610289 Free PMC article.
Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
Khalique S, Naidoo K, Attygalle AD, Kriplani D, Daley F, Lowe A, Campbell J, Jones T, Hubank M, Fenwick K, Matthews N, Rust AG, Lord CJ, Banerjee S, Natrajan R. Khalique S, et al. Among authors: natrajan r. J Pathol Clin Res. 2018 Jul;4(3):154-166. doi: 10.1002/cjp2.103. Epub 2018 Jul 20. J Pathol Clin Res. 2018. PMID: 29659191 Free PMC article.
Real-time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study.
Barrow-McGee R, Procter J, Owen J, Woodman N, Lombardelli C, Kothari A, Kovacs T, Douek M, George S, Barry PA, Ramsey K, Gibson A, Buus R, Holgersen E, Natrajan R, Haider S, Shattock MJ, Gillett C, Tutt AN, Pinder SE, Naidoo K. Barrow-McGee R, et al. Among authors: natrajan r. J Pathol. 2020 Mar;250(3):262-274. doi: 10.1002/path.5367. Epub 2019 Dec 22. J Pathol. 2020. PMID: 31755096 Free PMC article.
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
Peck B, Bland P, Mavrommati I, Muirhead G, Cottom H, Wai PT, Maguire SL, Barker HE, Morrison E, Kriplani D, Yu L, Gibson A, Falgari G, Brennan K, Farnie G, Buus R, Marlow R, Novo D, Knight E, Guppy N, Kolarevic D, Susnjar S, Milijic NM, Naidoo K, Gazinska P, Roxanis I, Pancholi S, Martin LA, Holgersen EM, Cheang MCU, Noor F, Postel-Vinay S, Quinn G, McDade S, Krasny L, Huang P, Daley F, Wallberg F, Choudhary JS, Haider S, Tutt AN, Natrajan R. Peck B, et al. Among authors: natrajan r. Cancer Res. 2021 Feb 15;81(4):847-859. doi: 10.1158/0008-5472.CAN-20-1822. Epub 2021 Jan 28. Cancer Res. 2021. PMID: 33509944 Free PMC article.
Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma.
Khalique S, Nash S, Mansfield D, Wampfler J, Attygale A, Vroobel K, Kemp H, Buus R, Cottom H, Roxanis I, Jones T, von Loga K, Begum D, Guppy N, Ramagiri P, Fenwick K, Matthews N, Hubank MJF, Lord CJ, Haider S, Melcher A, Banerjee S, Natrajan R. Khalique S, et al. Among authors: natrajan r. Cancers (Basel). 2021 Jul 30;13(15):3854. doi: 10.3390/cancers13153854. Cancers (Basel). 2021. PMID: 34359755 Free PMC article.
133 results